Physician profile
Anthony Malone
NPI 1033172952
$999.32
in general payments reported to CMS, 2019-2025
22 companies · $118 in 2025
The $118 reported for 2025 was more than what a typical Developmental - Behavioral Pediatrics provider received nationally (typical 2025 total: $79.84).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $182 · 2021: $171 · 2022: $126 · 2023: $168 · 2024: $73.80 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $359.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $222.52 | 2019-2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $130.11 | 2022-2025 | Qelbree, Qelbree |
| Sanofi-Aventis U.S. LLC | $85.86 | 2025 | |
| Tris Pharma INC | $81.96 | 2020-2021 | |
| Glaxosmithkline, LLC. | $65.74 | 2019-2023 | Bexsero, Pediarix |
| Arbor Pharmaceuticals, INC. | $55.55 | 2022 | |
| Sobi, INC | $51.60 | 2020-2022 | |
| Neurelis, INC. | $43.82 | 2021 | |
| Sanofi Pasteur INC. | $32.94 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $26.19 | 2019 | |
| Merck Sharp & Dohme LLC | $23.28 | 2021 | |
| Pfizer INC. | $21.16 | 2024 | |
| Kaleo, INC. | $19.93 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $19.92 | 2023 | Kristalose |
| Biogen, INC. | $19.75 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $18.43 | 2020 | |
| Genzyme Corporation | $17.40 | 2023 | |
| Collegium Pharmaceutical, INC. | $14.40 | 2025 | Jornay Pm |
| Seqirus USA INC | $13.42 | 2023 | Flucelvax Quadrivalent |
| Alexion Pharmaceuticals, INC. | $12.00 | 2019 | |
| Greenwich Biosciences, INC. | $11.97 | 2020 | |
| Travere Therapeutics, INC. | $11.37 | 2023 | Cholbam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Malone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.